PARTNER II Trial: Placement of AoRTic TraNscathetER Valves II - XT Intermediate and High Risk

A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 2032 participants.

Also called NCT01314313

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 2,032 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01314313
Other papers using this trial's data
  • 10-Year Randomized Outcomes of Transcatheter or Surgical Aortic Valve Replacement in Intermediate-Risk Aortic Stenosis Journal of the American College of Cardiology, 2026-06-16 DOI, PubMed 42300821
  • Cost-Effectiveness of Transcatheter Versus Surgical Aortic Valve Replacement in Patients With Severe Aortic Stenosis at Intermediate Risk Circulation, 2019-02-12 DOI, PubMed 30586747
  • Five-Year Outcomes of Transcatheter or Surgical Aortic-Valve Replacement The New England journal of medicine, 2020-02-27 DOI, PubMed 31995682
  • Health Status Benefits of Transcatheter vs Surgical Aortic Valve Replacement in Patients With Severe Aortic Stenosis at Intermediate Surgical Risk: Results From the PARTNER 2 Randomized Clinical Trial JAMA cardiology, 2017-08-01 DOI, PubMed 28658491, PMC5710586 Not in the PMC Open Access subset.
  • Incidence and Clinical Significance of Worsening Tricuspid Regurgitation Following Surgical or Transcatheter Aortic Valve Replacement: Analysis From the PARTNER IIA Trial Circulation. Cardiovascular interventions, 2021-08 DOI, PubMed 34266311
  • One-Year Clinical Outcomes With SAPIEN 3 Transcatheter Aortic Valve Replacement in High-Risk and Inoperable Patients With Severe Aortic Stenosis Circulation, 2016-07-12 DOI, PubMed 27400898
  • Transcatheter or Surgical Aortic-Valve Replacement in Intermediate-Risk Patients The New England journal of medicine, 2016-04-28 DOI, PubMed 27040324

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Canada (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01314313. Randomized; no masking; primary purpose treatment. Start 2011-03 (actual); primary completion 2016-01 (actual). Results posted on 2018-08-14.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
PARTNER II Trial: Placement of AoRTic TraNscathetER Valves II - XT Intermediate and High Risk
Acronym
PII A
Condition
Symptomatic Severe Aortic Stenosis
Intervention (Device)
TAVR Implantation with SAPIEN XT
Intervention (Device)
SAVR Implantation
Lead sponsor
Edwards Lifesciences (class: industry)

Record details

Record id
cardio:ct-nct01314313
Content hash
1e06a932c513ded99110dce3e4bb958de306656774cb95eb30173bdaae9f28ed